---
id: COVID-19-peripheral-ground-glass_151
category: radiology
tags: [COVID-19, SARS-CoV-2, peripheral-ground-glass, crazy-paving, chest-radiology, CT]
deck: Infectious Diseases
created: 2025-11-11
modified: 2025-11-11
---

## COVID-19 Pneumonia - Peripheral Ground-Glass Opacities

**Q:** What are the characteristic CT findings of COVID-19 pneumonia including distribution, temporal evolution, and how it differs from other viral pneumonias?

**A:**

## DEFINITION

**COVID-19 Pneumonia:** **"Viral pneumonia caused by SARS-CoV-2, characterized by bilateral peripheral ground-glass opacities with or without consolidation"**

**Hallmark:** **Peripheral, bilateral, ground-glass opacities**

**Key Point:** **Peripheral ground-glass opacities (GGO) = most common COVID-19 finding** (>80%)

---

## CT FINDINGS

**Hallmark: Bilateral Peripheral Ground-Glass Opacities**

### **Mnemonic: "PERIPHERAL COVID"**

**P**eripheral distribution (subpleural) - **hallmark**
**E**arly: Ground-glass opacities (GGO)
**R**ight and left (bilateral - 90%)
**I**nterlobular septal thickening (crazy-paving)
**P**osterior > anterior (dependent areas)
**H**alo sign (rare - organizing pneumonia)
**E**xtensive in severe disease (diffuse)
**R**ound morphology (nodular GGO)
**A**ir bronchograms (if consolidation)
**L**ower lobes > upper lobes

**C**razy-paving pattern (GGO + septal thickening)
**O**rganizing pneumonia (late phase)
**V**ascular enlargement (within GGO)
**I**nterstitial thickening
**D**iffuse (if severe - ARDS)

**Key Point:** **Bilateral peripheral GGO = COVID-19** (until proven otherwise in pandemic context)

---

## TEMPORAL EVOLUTION (4 STAGES)

**Mnemonic: "EARLY-PEAK-CONSOLIDATE-RESOLVE"**

### **Stage 1: Early (Day 0-4):**
- **Ground-glass opacities** (focal or multifocal)
- **Unilateral or bilateral** (may be subtle)
- **Round morphology**
- **Lower lobes**
- **CT may be normal** (10-20% at symptom onset)

**Key Point:** **Early = focal GGO** (may be normal initially)

---

### **Stage 2: Progressive (Day 5-8):**
- **Ground-glass opacities increase**
- **Bilateral, multifocal**
- **Peripheral distribution** becomes prominent
- **Crazy-paving pattern** (GGO + interlobular septal thickening)
- **Consolidation begins** (organizing pneumonia)

**Key Point:** **Progressive = bilateral peripheral GGO + crazy-paving**

---

### **Stage 3: Peak (Day 9-13):**
- **Peak extent** (maximum lung involvement)
- **Dense consolidation** (organizing pneumonia)
- **Crazy-paving prominent**
- **Traction bronchiectasis** (early fibrosis)
- **Architectural distortion**

**Key Point:** **Peak = dense consolidation + crazy-paving** (worst imaging)

---

### **Stage 4: Absorption (Day 14+):**
- **Gradual resolution**
- **GGO decreases**
- **Consolidation resolves**
- **Residual:** Ground-glass, fibrosis, traction bronchiectasis

**Key Point:** **Absorption = gradual resolution** (may take weeks to months)

---

## DISTRIBUTION CHARACTERISTICS

**Location:**
- **Peripheral (subpleural)** - 80-90%
- **Posterior > anterior** (dependent areas)
- **Lower lobes > upper lobes** (70-80%)
- **Bilateral** (90% at peak)

**Pattern:**
- **Multifocal** (multiple areas)
- **Patchy** (not homogeneous)
- **Spares central lung** (peripheral predominance)

**Key Point:** **Peripheral + posterior + lower lobes = characteristic distribution**

---

## CRAZY-PAVING PATTERN

**Definition:** **"Ground-glass opacity with superimposed interlobular septal thickening"**

**Appearance:** Resembles irregular paving stones

**Incidence in COVID-19:** 30-50% (progressive and peak stages)

**Mechanism:**
- **GGO:** Alveolar damage, edema
- **Septal thickening:** Interstitial edema, inflammation, fibrosis

**Differential of Crazy-Paving:**
- **COVID-19** (most common in pandemic)
- **PCP** (HIV patients)
- **Pulmonary alveolar proteinosis** (PAP)
- **Pulmonary edema** (cardiogenic, ARDS)
- **Organizing pneumonia** (COP)

**Key Point:** **Crazy-paving in COVID-19 = progressive/peak stage** (Day 5-13)

---

## VASCULAR ENLARGEMENT

**CT Finding:** **Dilated vessels within or adjacent to ground-glass opacities**

**Incidence:** 70-80% of COVID-19 cases

**Mechanism:**
- **Vascular inflammation** (endothelitis)
- **Microthrombi** (hypercoagulable state)
- **Increased blood flow** (inflammatory response)

**Key Point:** **Vascular enlargement = distinguishing feature** of COVID-19 (vs other viral pneumonias)

---

## COVID-19 vs OTHER VIRAL PNEUMONIAS

| **Feature** | **COVID-19** | **Influenza** | **Other Viral (RSV, etc)** |
|-------------|--------------|---------------|----------------------------|
| **Distribution** | **Peripheral (subpleural)** | **Central, peribronchovascular** | Central or diffuse |
| **GGO** | **Bilateral, multifocal** | Bilateral, patchy | Bilateral, patchy |
| **Consolidation** | **Organizing pneumonia** | Bronchopneumonia pattern | Bronchopneumonia |
| **Crazy-paving** | **Common (30-50%)** | Less common | Rare |
| **Vascular enlargement** | **Prominent (70-80%)** | Less prominent | Minimal |
| **Nodules** | **Round GGO nodules** | Tree-in-bud | Tree-in-bud |
| **Pleural effusion** | **Rare (<5%)** | Uncommon | Uncommon |

**Key Point:** **Peripheral GGO + vascular enlargement = COVID-19** (vs central distribution in influenza)

---

## CT FINDINGS BY SEVERITY

### **Mild:**
- **Focal GGO** (unilateral or bilateral)
- **<25% lung involvement**
- **No consolidation**

### **Moderate:**
- **Bilateral multifocal GGO**
- **25-50% lung involvement**
- **Mild consolidation**
- **Crazy-paving pattern**

### **Severe:**
- **Diffuse bilateral GGO + consolidation**
- **>50% lung involvement**
- **Dense consolidation** (organizing pneumonia)
- **ARDS pattern** (diffuse bilateral)
- **Traction bronchiectasis** (early fibrosis)

**Key Point:** **Extent of involvement correlates with severity**

---

## ATYPICAL FINDINGS (LESS COMMON)

**Rare in COVID-19 (<5% each):**
- **Pleural effusion** (<5%, suggests superinfection)
- **Lymphadenopathy** (<5%, suggests superinfection)
- **Cavitation** (rare, suggests superinfection or fungal)
- **Pneumothorax** (rare, mechanical ventilation complication)

**If Present, Consider:**
- **Bacterial superinfection** (effusion, LAD)
- **Fungal superinfection** (cavitation - Aspergillus, Mucor)
- **Pulmonary embolism** (hypercoagulable)

**Key Point:** **Pleural effusion or LAD = atypical** (consider superinfection)

---

## COMPLICATIONS

**Mnemonic: "ARDS-EMBOLI-FIBROSIS"**

**A**RDS (acute respiratory distress syndrome - severe)
**R**eorganizing pneumonia (late complication)
**D**iffuse alveolar damage (pathology)
**S**econdary bacterial/fungal infection

**E**mboli (pulmonary embolism - hypercoagulable state)
**M**echanical ventilation complications (barotrauma, PTX)
**B**acterial superinfection (S. aureus, Pseudomonas)
**O**rganizing pneumonia (post-acute COVID syndrome)
**L**ong COVID (persistent symptoms)
**I**nvasive fungal infection (Aspergillus, Mucor - if steroids/immunosuppression)

**F**ibrosis (post-COVID pulmonary fibrosis)
**I**nterstitial lung disease (ILD pattern)
**B**ronchiectasis (traction)
**R**eticulation (late)
**O**rganizing pneumonia
**S**evere ARDS (30-40% mortality)
**I**ntensive care (mechanical ventilation)
**S**econdary infections

**Key Point:** **ARDS, PE, secondary infections = major complications**

---

## DIAGNOSIS

**RT-PCR (Gold Standard):**
- **Nasopharyngeal swab**
- **Sensitivity:** 70-95% (depends on timing, technique)
- **False negatives possible** (repeat if high suspicion)

**Antigen Test:**
- **Rapid** (15-30 minutes)
- **Less sensitive** (60-80%)
- **High specificity** (>95%)

**Serology:**
- **IgM/IgG antibodies**
- **Not useful acutely** (seroconversion takes 1-2 weeks)

**Imaging:**
- **CT sensitivity:** 90-97% (at peak, Day 9-13)
- **CT may be normal** early (Day 0-4)

**Key Point:** **RT-PCR = gold standard** (CT highly sensitive at peak)

---

## MANAGEMENT

**Mild (Outpatient):**
- **Supportive care** (rest, hydration)
- **Monitor O2 saturation**
- **Antiviral:** Nirmatrelvir-ritonavir (Paxlovid) if high risk

**Moderate-Severe (Hospitalized):**
- **Supplemental oxygen**
- **Dexamethasone** 6mg daily x 10 days (if requiring O2)
- **Remdesivir** (if early, requiring O2)
- **Anticoagulation** (prophylactic or therapeutic)

**Critical (ICU/ARDS):**
- **Mechanical ventilation** (lung-protective strategy)
- **Prone positioning**
- **ECMO** (if refractory hypoxemia)
- **Dexamethasone** 6mg daily x 10 days
- **Therapeutic anticoagulation** (if PE suspected)

**Key Point:** **Dexamethasone reduces mortality** in severe COVID-19 requiring O2

---

## PROGNOSIS

**Imaging Resolution:**
- **Mild:** 2-4 weeks
- **Moderate:** 4-8 weeks
- **Severe:** 8-12+ weeks (may have persistent changes)

**Residual Changes:**
- **Ground-glass opacities** (may persist months)
- **Fibrosis** (5-20% of severe cases)
- **Traction bronchiectasis**

**Mortality:**
- **Overall:** 1-3% (varies by age, comorbidities, vaccination status)
- **ARDS:** 30-40%

**Key Point:** **Severe disease may have persistent fibrosis** (5-20%)

---

**Clinical Pearls:**
- **Bilateral peripheral ground-glass opacities = COVID-19** (most common finding, >80%)
- **Peripheral + posterior + lower lobes = characteristic distribution**
- **Temporal evolution: Focal GGO → bilateral GGO → consolidation → resolution**
- **Crazy-paving pattern in 30-50%** (progressive/peak stage, Day 5-13)
- **Vascular enlargement = distinguishing feature** (70-80%, vs other viral pneumonias)
- **Pleural effusion or LAD = atypical** (<5%, consider superinfection)
- **CT may be normal early** (Day 0-4, 10-20% of cases)
- **Peak imaging: Day 9-13** (worst extent)
- **RT-PCR = gold standard diagnosis** (CT highly sensitive at peak)
- **Dexamethasone 6mg daily reduces mortality** (if requiring O2)
- **Complications: ARDS, PE, secondary infections** (bacterial, fungal)

**Media:**

**Image 1 - COVID-19 (Early Stage):**

*CT chest Day 3 of symptoms showing focal ground-glass opacities in bilateral lower lobes, peripheral distribution. Round morphology. This represents early stage COVID-19. Patient: 45-year-old with fever, cough. RT-PCR positive for SARS-CoV-2.*

**Image 2 - COVID-19 (Progressive Stage with Crazy-Paving):**

*CT Day 7 demonstrating bilateral multifocal peripheral ground-glass opacities with superimposed interlobular septal thickening (crazy-paving pattern). Note vascular enlargement within GGO areas. Patient developed hypoxemia requiring supplemental oxygen.*

**Image 3 - COVID-19 (Peak Stage with Consolidation):**

*CT Day 10 showing extensive bilateral peripheral ground-glass opacities and consolidation (organizing pneumonia pattern). Dense crazy-paving. This represents peak stage with maximum lung involvement. Patient required ICU admission, mechanical ventilation, prone positioning.*

**Image 4 - Temporal Evolution (Serial CTs):**

*(A) Day 3 - focal GGO. (B) Day 7 - bilateral peripheral GGO + crazy-paving. (C) Day 10 - peak consolidation. (D) Day 21 - gradual resolution. Demonstrates characteristic temporal progression of COVID-19 pneumonia.*

**Additional Resources:**
- **Radiopaedia.org:** Search "COVID-19 pneumonia," "SARS-CoV-2 imaging"
- **Radiology 2020:** Temporal changes of CT findings in 90 patients with COVID-19
- **NIH COVID-19 Treatment Guidelines**

**Sources:** [Radiopaedia - COVID-19 Pneumonia], [Radiology 2020 - Temporal CT Changes], [NIH COVID-19 Treatment Guidelines]
